Dr. Aditya Gupta is a dermatologist in London, Ontario, and medical director of Mediprobe Research. He is a prominent speaker, and researcher, heavily involved in clinical research with a focus on superficial fungal infections such as onychomycosis. Dr. Gupta also contributes to SkinTherapyLetter as an advisory board member.
STL Index for: Gupta Aditya K.
Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis
Early clinical trial data indicate the increasing effectiveness and safety of efinaconazole 10% solution use beyond 12 months; application for up to 24 months appears to remain safe even for elderly patients.
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis
Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis.
Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis
Update and discussion on onychomycosis (nail fungus) and Efinaconazole 10%. Recent clinical trial results, and discussion about patient safety profile, special cases like diabetic patients, and cure rates.
Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa
Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Discussion includes, safety and efficacy in clinical trials.
Nivolumab for Metastatic Melanoma
Melanoma is an aggressive skin cancer with a generally poor prognosis at Stage III-IV disease. Discussion centres around clinical trial data from phase I-III studies of Nivolumab (Opdivo®), a human monoclonal antibody which prevents immune inhibition by interacting with PD-1 on tumor cells.
Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis
Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.
Ivermectin 1% Cream for Rosacea
The etiology of papulopustular rosacea (PPR) is not well understood yet appears to involve both the innate and adaptive immune response in addition to possible infestation with Demodex mites. This article reviews data on Ivermectin cream 1%, a new topical treatment for PPR.
Sinecatechins 10% Ointment: A Green Tea Extract for the Treatment of External Genital Warts
External genital warts resulting from HPV are a common sexually transmitted infection. This article reviews data on Sinecatechins 10% ointment (a Green Tea extract), a new botanically based patient-administered therapy for external genital warts.
5% Minoxidil: Treatment for Female Pattern Hair Loss
Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. This article review recent Phase III clinical trials on Minoxidil efficacy for the treatment of female patter hair loss.
Onychomycosis Diagnosis and Emerging Therapy
Onychomycosis is a common nail disorder for which successful treatment can be clinically challenging. Diagnosis, treatment, and management using various modalities are discussed.
Efinaconazole: A New Topical Treatment for Onychomycosis
Nail fungus, left untreated, the infection can spread to other nails and potentially cause further complications. This article reviews efinaconazole 10% as a topical monotherapy. Clinical trial data, mechanism of action, and future treatments are discussed.
Device-Based Therapies for Onychomycosis Treatment
Device-based therapies are promising alternatives for the treatment of onychomycosis because they can mitigate some of the negative factors associated with treatment failure. This article reviews the case for laser and light based therapies, for the treatment of nail fungus.
A Simple Algorithm for the Treatment of Dermatophyte Toenail Onychomycosis
There has been much discussion about the optimal treatment for onychomycosis. We propose a simple algorithmic approach to aid in the selection of therapy for dermatophyte toenail onychomycosis and present a balance between efficacy and risk of therapy.
Ciclopirox Nail Lacquer 8% for the Treatment of Onychomycosis: A Canadian Perspective
Onychomycosis is prevalent, and risk factors, such as old age and diabetes, are increasing. This condition has been treated using oral antifungal agents with varying degrees of success. Recently, ciclopirox nail lacquer 8% solution became the first topical agent approved in Canada for onychomycosis.
A Review of Prednicarbate (Dermatop®)
Prednicarbate is a nonhalogenated corticosteroid that is used in the treatment of inflammatory skin diseases, for example atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.
Ciclopirox (Loprox®) Gel for Superficial Fungal Infections
Ciclopirox (Loprox®) is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Ciclopirox is indicated in the US for the treatment of tinea pedis, tinea corporis, pityriasis versicolor, seborrheic dermatitis, and cutaneous candidiasis.
Ciclopirox Shampoo for Treating Seborrheic Dermatitis
Seborrheic dermatitis is a common inflammatory skin disease, affecting between 1% and 3% of immunocompetent adults. While its cause is unknown, a number of predisposing factors have been reported, including the implications of Malassezia yeasts.
Lustra®, Lustra-AF® and Alustra™
Hydroquinone has been successfully used to treat hyperpigmentation for many years. Recently, new formulations containing hydroquinone have become available, including Lustra® and Lustra-AF®. These products also contain glycolic acid 2%, an active antioxidant system, and moisturizers.
The Scoring Clinical Index for Onychomycosis (SCIO Index)
Onychomycosis is a common disease, and there are a number of factors that may affect the duration and dosage of treatment including the type of onychomycosis, the area and thickness of nail involvement, the age of the patient, and the location of the digit that is affected.
Butenafine: An Update of Its Use in Superficial Mycoses
Butenafine may be effective and safe in the treatment of interdigital tinea pedis (apply twice daily for 1 week or once daily for 4 weeks), tinea corporis/ tinea cruris (apply twice daily for 2 weeks), and pityriasis versicolor (apply once daily for two weeks).
Topical Metronidazole for Rosacea
Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age. It is more common in women, but may be more severe in men. Currently there is no cure available for rosacea, but it can be controlled with topical and oral drug therapy.
Antidepressant Drugs in Dermatology
Antidepressant drugs can be an important component of the dermatologist’s armamentarium. Specific guidelines, side effect profile, drug-drug interactions, and the current indications should always be obtained for any particular antidepressant agent before it is prescribed.
Ciclopirox Nail Lacquer Topical Solution 8%
Ciclopirox nail lacquer 8% (Penlac, Aventis Pharma) was approved by the US FDA in December 1999, as a component of a comprehensive management program, for use in immunocompetent patients who have mild to moderate onychomycosis of the fingers and toes without lunula involvement due to Trichophyton rubrum.
The Skin-Cap® Story
A review of the history surrounding the Skin-Cap controversy as it unfolded.
